About Kite Pharma
Kite Pharma is a company based in Los Angeles (United States) founded in 2009 was acquired by Gilead in August 2017. It operates as a HealthTech. Kite Pharma has raised $97.7 million across 7 funding rounds from investors including Gilead, Amgen Business Development and Alta Partners. The company has 17 employees as of December 31, 2022. Kite Pharma has completed 4 acquisitions, including Cell Design Labs, Gadeta and Interius Biotherapeutics. Kite Pharma offers products and services including Yescarta and CAR T-Cell Therapy. Kite Pharma operates in a competitive market with competitors including Senti Biosciences, Caribou Biosciences, Poseida Therapeutics, Immunocore and Juno Therapeutics, among others.
- Headquarter Los Angeles, United States
- Employees 17 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gilead Sciences, Inc.
-
Annual Revenue
$294 M (USD)-66as on Dec 31, 2024
-
Net Profit
$480 M (USD)-92as on Dec 31, 2024
-
EBITDA
$1.66 B (USD)-78as on Dec 31, 2024
-
Total Equity Funding
$97.7 M (USD)
in 7 rounds
-
Latest Funding Round
$300 M (USD), Post-IPO
Apr 03, 2018
-
Investors
Gilead
& 5 more
-
Employee Count
17
as on Dec 31, 2022
-
Investments & Acquisitions
Cell Design Labs
& 3 more
-
Acquired by
Gilead
(Aug 25, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kite Pharma
Kite Pharma offers a comprehensive portfolio of products and services, including Yescarta and CAR T-Cell Therapy.
Yescarta is used for treating blood cancer effectively.
Custom therapy is developed for blood cancer treatment.
People of Kite Pharma
Unlock access to complete
Unlock access to complete
Leadership Team
294 people
Software Development Team
183 people
Senior Team
62 people
Legal and Compliance
41 people
Data Analysis and Operations Team
38 people
Human Resources and Administration
38 people
Operations Team
38 people
Finance and Accounting
36 people
Unlock access to complete
Funding Insights of Kite Pharma
Kite Pharma has successfully raised a total of $97.7M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $300 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kite Pharma
Kite Pharma has secured backing from 6 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Gilead, Amgen Business Development and Alta Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are facilitated by Amgen-backed entity.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked | |
|
Pontifax Venture Capital is focused on life sciences investments.
|
Locked | Locked | Locked |
Investor details for Kite Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kite Pharma
Kite Pharma has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Cell Design Labs, Gadeta and Interius Biotherapeutics.
Investment portfolio details for Kite Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of gene therapies for treating multiple diseases
|
Locked | Locked | 2020 | Locked | |
|
CAR T-cell immunotherapies for cancer and diseases are developed.
|
Locked | Locked | 2016 | Locked | |
|
T Cell based cancer therapies based on gamma delta (γδ) T cell receptors
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Kite Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Kite Pharma
Detailed financials for Kite Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kite Pharma Comparisons
Peer comparison for Kite Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kite Pharma
Kite Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Caribou Biosciences, Poseida Therapeutics, Immunocore and Juno Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
Detailed competitors of Kite Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kite Pharma
Complete news archive for Kite Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kite Pharma
Kite Pharma was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Kite Pharma is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Kite Pharma is a funded company, having raised a total of $97.7M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Kite Pharma is 17.
Annual revenue of Kite Pharma is $294M as on Dec 31, 2024.
Kite Pharma is dedicated to advancing cell therapy solutions for cancer treatment. The company specializes in CAR T-cell therapy, a personalized treatment designed to harness the immune system against blood cancers. Research and development efforts are directed toward improving patient responses, exploring diverse therapy modalities, and enhancing manufacturing speed. Operations are centered in the healthcare and biotechnology sector with a mission to achieve cures for cancer.
Kite Pharma's top competitors include Immunocore, Juno Therapeutics and Lyell Immunopharma.
Kite Pharma offers Yescarta and CAR T-Cell Therapy.
Kite Pharma has made 4 acquisitions, including Cell Design Labs, Gadeta, and Interius Biotherapeutics.
Kite Pharma has 6 investors. Key investors include Gilead, Amgen Business Development, Alta Partners, Pontifax Venture Capital, and Arie Belldegrun.